Identification of Purple Acid Phosphatase Inhibitors by Fragment-Based Screening: Promising New Leads for Osteoporosis Therapeutics

Chemical Biology and Drug Design

Volumn 80, Issue 5, 2012, Pages 665-674

  Feder, Daniel ^a   Hussein, Waleed M ^a,b   Clayton, Daniel J ^a   Kan, Meng Wei ^a   Schenk, Gerhard ^a,c   McGeary, Ross P ^a   Guddat, Luke W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Helwan   (Egypt)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Crystallography; Drug design; Fragment screening; Osteoporosis; Purple acid phosphatase; X ray

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; HYDROXYL GROUP; ORGANOPHOSPHATE;

ARTICLE; COMPETITIVE INHIBITION; CONFORMATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG IDENTIFICATION; HYDROGEN BOND; HYDROLYSIS; MOLECULAR DOCKING; MOLECULAR RECOGNITION; NONHUMAN; OSTEOPOROSIS; PHASEOLUS VULGARIS; PRIORITY JOURNAL; PROTEIN BINDING; SCREENING; SEQUENCE ALIGNMENT; STATIC ELECTRICITY; SWINE; X RAY CRYSTALLOGRAPHY;

ACID PHOSPHATASE; AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; GLYCOPROTEINS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; OSTEOPOROSIS; PHASEOLUS; SWINE;

ANIMALIA; FUNGI;

EID: 84867230278     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12001     Document Type: Article

References (52)

1. Mitić N., Smith S.J., Neves A., Guddat L.W., Gahan L.R., Schenk G. (2006) The catalytic mechanisms of binuclear metallohydrolases. Chem Rev;106:3338-3363.
2. Gaber B.P., Sheridan J.P., Bazer F.W., Roberts R.M. (1979) Resonance Raman scattering from uteroferrin, the purple glycoprotein of the porcine uterus. J Biol Chem;254:8340-8342.
3. Yang Y.S., McCormick J.M., Solomon E.I. (1997) Circular dichroism and magnetic circular dichroism studies of the mixed-valence binuclear non-heme iron active site in uteroferrin and its anion complexes. J Am Chem Soc;119:11832-11842.
4. Wang D.L., Holz R.C., David S.S., Que L. Jr, Stankovich M.T. (1991) Electrochemical properties of the diiron core of uteroferrin and its anion complexes. Biochemistry;30:8187-8194.
5. Bernhardt P.V., Schenk G., Wilson G.J. (2004) Direct electrochemistry of porcine purple acid phosphatase (uteroferrin). Biochemistry;43:10387-10392.
6. Beck J.L., McConachie L.A., Summors A.C., Arnold W.N., de Jersey J., Zerner B. (1986) Properties of a purple phosphatase from red kidney bean - a zinc-iron metalloenzyme. Biochim Biophys Acta;869:61-68.
7. Schenk G., Ge Y., Carrington L.E., Wynne C.J., Searle I.R., Carroll B.J., Hamilton S., de Jersey J. (1999) Binuclear metal centers in plant purple acid phosphatases: Fe-Mn in sweet potato and Fe-Zn in soybean. Arch Biochem Biophys;370:183-189.
8. Sträter N., Jasper B., Scholte M., Krebs B., Duff A.P., Langley D.B., Han R., Averill B.A., Freeman C.H., Guss J.M. (2005) Crystal structures of recombinant human purple acid phosphatase with and without an inhibitory conformation of the repression loop. J Mol Biol;351:233-246.
9. Guddat L.W., McAlpine A.S., Hume D., Hamilton S., de Jersey J., Martin J.L. (1999) Crystal structure of mammalian purple acid phosphatase. Structure;7:757-767.
10. Uppenberg J., Lindqvist F., Svensson C., Ek-Rylander B., Andersson G. (1999) Crystal structure of a mammalian purple acid phosphatase. J Mol Biol;290:201-211.
11. Lindqvist Y., Johansson E., Kaija H., Vihko P., Schneider G. (1999) Three-dimensional structure of a mammalian purple acid phosphatase at 2.2 Å resolution with a mu-(hydr)oxo bridged di-iron center. J Mol Biol;291:135-147.
12. Schenk G., Gahan L.R., Carrington L.E., Mitić N., Valizadeh M., Hamilton S.E., de Jersey J., Guddat L.W. (2005) Phosphate forms an unusual tripodal complex with the Fe-Mn center of sweet potato purple acid phosphatase. Proc Natl Acad Sci U S A;102:273-278.
13. Sträter N., Klabunde T., Tucker P., Witzel H., Krebs B. (1995) Crystal structure of a purple acid phosphatase containing a dinuclear Fe(III)-Zn(II) active site. Science;268:1489-1492.
14. Schlosnagle D.C., Bazer F.W., Tsibris J.C., Roberts R.M. (1974) An iron-containing phosphatase induced by progesterone in the uterine fluids of pigs. J Biol Chem;249:7574-7579.
15. Oddie G.W., Schenk G., Angel N.Z., Walsh N., Guddat L.W., de Jersey J., Cassady A.I., Hamilton S.E., Hume D.A. (2000) Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone;27:575-584.
16. Zaidi M., Moonga B., Moss D.W., MacIntyre I. (1989) Inhibition of osteoclastic acid phosphatase abolishes bone resorption. Biochem Biophys Res Commun;159:68-71.
17. Janckila A.J., Parthasarathy R.N., Parthasarathy L.K., Seelan R.S., Yam L.T. (2002) Stable expression of human tartrate-resistant acid phosphatase isoforms by CHO cells. Clin Chim Acta;326:113-122.
18. Halleen J.M., Räisänen S.R., Salo J.J., Reddy S.V., Roodman G.D., Hentunen T.A., Lehenkari P.P., Kaija H., Vikho P., Vaananen H.K. (1999) Intracellular fragmentation of bone resorption fragments by ROS generated by osteoclastic TRAP. J Biol Chem;274:22907-22910.
19. Cashikar A.G., Kumaresan R., Rao N.M. (1997) Biochemical characterization and subcellular localization of the red kidney bean purple acid phosphatase. Plant Physiol;114:907-915.
20. Bozzo G.G., Singh V.K., Plaxton W.C. (2004) Phosphate or phosphite addition promotes the proteolytic turnover of phosphate-starvation inducible tomato purple acid phosphatase isozymes. FEBS Lett;573:51-54.
21. Hayman A.R., Cox T.M. (2003) Tartrate-resistant acid phosphatase knockout mice. J Bone Miner Res;18:1905-1907.
22. Angel N.Z., Walsh N., Forwood M.R., Ostrowski M.C., Cassady A.I., Hume D.A. (2000) Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res;15:103-110.
23. Schindelmeiser J., Gullotta F., Munstermann D. (1989) Purple acid phosphatase of human brain macrophages in AIDS encephalopathy. Pathol Res Pract;185:184-186.
24. Schindelmeiser J., Radzun H.J., Munstermann D. (1991) Tartrate-resistant, purple acid phosphatase in Gaucher cells of the spleen. Immuno- and cytochemical analysis. Pathol Res Pract;187:209-213.
25. Hoyer J.D., Li C.Y., Yam L.T., Hanson C.A., Kurtin P.J. (1997) Immunohistochemical demonstration of acid phosphatase isoenzyme 5 (tartrate-resistant) in paraffin sections of hairy cell leukemia and other hematologic disorders. Am J Clin Pathol;108:308-315.
26. Lang P., Schultzberg M., Andersson G. (2001) Expression and distribution of tartrate-resistant purple acid phosphatase in the rat nervous system. J Histochem Cytochem;49:379-396.
27. Chung Y.C., Ku C.H., Chao T.Y., Yu J.C., Chen M.M., Lee S.H. (2006) Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev;15:424-428.
28. Tanko L.B., Karsdal M.A., Christiansen C., Leeming D.J. (2006) Biochemical approach to the detection and monitoring of metastatic bone disease: what do we know and what questions need answers? Cancer Metastasis Rev;25:659-668.
29. Pinkse M.W., Merkx M., Averill B.A. (1999) Fluoride inhibition of bovine spleen purple acid phosphatase: characterization of a ternary enzyme-phosphate-fluoride complex as a model for the active enzyme-substrate-hydroxide complex. Biochemistry;38:9926-9936.
30. Crans D.C., Simone C.M., Holz R.C., Que L. Jr. (1992) Interaction of porcine uterine fluid purple acid phosphatase with vanadate and vanadyl cation. Biochemistry;31:11731-11739.
31. Valizadeh M., Schenk G., Nash K., Oddie G.W., Guddat L.W., Hume D.A., de Jersey J., Burke T.R. Jr, Hamilton S. (2004) Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases. Arch Biochem Biophys;424:154-162.
32. McGeary R.P., Vella P., Mak J.Y., Guddat L.W., Schenk G. (2009) Inhibition of purple acid phosphatase with alpha-alkoxynaphthylmethylphosphonic acids. Bioorg Med Chem Lett;19:163-166.
33. Mohd-Pahmi S.H., Hussein W.M., Schenk G., McGeary R.P. (2011) Synthesis, modelling and kinetic assays of potent inhibitors of purple acid phosphatase. Bioorg Med Chem Lett;21:3092-3094.
34. Schwender C.F., Beers S.A., Malloy E., Demarest K., Minor L., Lau K.H.W. (1995) 1-naphthylmethylphosphonic acid-derivatives as osteoclastic acid-phosphatase inhibitors. Bioorg Med Chem Lett;5:1801-1806.
35. Fattori D., Squarcia A., Bartoli S. (2008) Fragment-based approach to drug lead discovery - Overview and advances in various techniques. Drugs in R&D;9:217-227.
36. Campbell H.D., Dionysius D.A., Keough D.T., Wilson B.E., de Jersey J., Zerner B. (1978) Iron-containing acid phosphatases: comparison of the enzymes from beef spleen and pig allantoic fluid. Biochem Biophys Res Commun;82:615-620.
37. Segel I.H. (1993) Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibria and Steady-State Equilibria. New York: John Wiley and Sons.
38. Schenk G., Elliott T.W., Leung E., Carrington L.E., Mitić N., Gahan L.R., Guddat L.W. (2008) Crystal structures of a purple acid phosphatase, representing different steps of this enzyme's catalytic cycle. BMC Struct Biol;8:6.
39. McPhillips T.M., McPhillips S.E., Chiu H.J., Cohen A.E., Deacon A.M., Ellis P.J., Garman E., Gonzalez A., Sauter N.K., Phizackerley R.P., Soltis S.M., Kuhn P. (2002) Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Radiat;9:401-406.
40. Kabsch W. (2010) XDS. Acta Crystallogr D Biol Crystallogr;66:125-132.
41. Collaborative Computational Project N (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr;50:760-763.
42. McCoy A.J. (2007) Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr D Biol Crystallogr;63:32-41.
43. Klabunde T., Sträter N., Frohlich R., Witzel H., Krebs B. (1996) Mechanism of Fe(III)-Zn(II) purple acid phosphatase based on crystal structures. J Mol Biol;259:737-748.
44. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J. et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr;66:213-221.
45. Murshudov G.N., Vagin A.A., Dodson E.J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr;53:240-255.
46. Emsley P., Cowtan K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr;60:2126-2132.
47. Thomsen R., Christensen M.H. (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem;49:3315-3321.
48. Mitić N., Valizadeh M., Leung E.W., de Jersey J., Hamilton S., Hume D.A., Cassady A.I., Schenk G. (2005) Human tartrate-resistant acid phosphatase becomes an effective ATPase upon proteolytic activation. Arch Biochem Biophys;439:154-164.
49. Schenk G., Carrington L.E., Hamilton S.E., de Jersey J., Guddat L.W. (1999) Crystallization and preliminary X-ray diffraction data for a purple acid phosphatase from sweet potato. Acta Crystallogr D Biol Crystallogr;55:2051-2052.
50. Schenk G., Korsinczky M.L., Hume D.A., Hamilton S., de Jersey J. (2000) Purple acid phosphatases from bacteria: similarities to mammalian and plant enzymes. Gene;255:419-424.
51. Flanagan J.U., Cassady A.I., Schenk G., Guddat L.W., Hume D.A. (2006) Identification and molecular modeling of a novel, plant-like, human purple acid phosphatase. Gene;377:12-20.
52. Wang Y., Andersson G. (2007) Expression and proteolytic processing of mammalian purple acid phosphatase in CHO-K1 cells. Arch Biochem Biophys;461:85-94.